Oxford (UK)
Since extending our seed financing round earlier this year, the first 4 months of 2025 have seen AlveoGene make good progress in generating world leading pre-clinical data sets for our development programs in Surfactant Protein Deficiencies SP-B and ABCA3, AATD Lung Disease, and IPF enabled by our InGenuiTy® inhaled gene therapy platform.
Building on the December 2024 announcement by Boehringer Ingelheim confirming the commencement of their Lenticlair Ph1 clinical trial in Cystic Fibrosis which is enabled by InGenuiTy®, we have confidence that our own product candidates will result in both first and best in class products that will transform rare respiratory disease outcomes and provide therapeutic solutions where there are none.
Click the link below for our latest corporate presentation.
